Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myeloma - PubMed
4 hours ago
- #sBCMA
- #biomarker
- #multiple myeloma
- Treatment-specific differences in soluble B-cell maturation antigen (sBCMA) levels at minimum residual disease (MRD) negativity in multiple myeloma were analyzed.
- Studies highlight sBCMA as a novel biomarker for predicting outcomes in multiple myeloma patients.
- Key treatments include BCMA-targeting bispecific antibodies (BCMA‐BsAb) and GPRC5D-targeting bispecific antibodies (GPRC5D‐BsAb).
- Research examines how sBCMA and non-T-cell factors impact refractoriness to BCMA-targeting T-cell engagers.
- Effects of therapies like teclistamab and talquetamab on sBCMA levels in relapsed/refractory multiple myeloma were investigated.